CONSULTING AGREEMENTConsulting Agreement • March 18th, 2013 • Synergy Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 18th, 2013 Company Industry JurisdictionThis CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of the 28th day of December 2012 by and between Gabriele M. Cerrone (“Consultant”) and Synergy Pharmaceuticals Inc., a Delaware corporation (the “Company”).
SECOND AMENDED AND RESTATED CONSULTING AGREEMENTConsulting Agreement • May 6th, 2011 • Synergy Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 6th, 2011 Company Industry JurisdictionThis SECOND AMENDED AND RESTATED CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of the 2nd day of May 2011 by and between Gabriele M. Cerrone (“Consultant”) and Synergy Pharmaceuticals, Inc., a Florida corporation (the “Company”).
AMENDED AND RESTATED CONSULTING AGREEMENTConsulting Agreement • February 5th, 2010 • Synergy Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 5th, 2010 Company Industry JurisdictionThis AMENDED AND RESTATED CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of the 1st day of February 2010 by and between Gabriele M. Cerrone (“Consultant”) and Synergy Pharmaceuticals, Inc., a Florida corporation (the “Company”).
CONSULTING AGREEMENTConsulting Agreement • April 15th, 2009 • Synergy Pharmaceuticals, Inc. • Retail-retail stores, nec • New York
Contract Type FiledApril 15th, 2009 Company Industry JurisdictionThis Agreement is made and entered into as of the 11th day of March, 2009 by and between Gabriele M. Cerrone (“Consultant”) and Synergy Pharmaceuticals, Inc., a Florida corporation (the “Company”).
AMENDED AND RESTATED CONSULTING AGREEMENTConsulting Agreement • April 15th, 2009 • Callisto Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledApril 15th, 2009 Company Industry JurisdictionThis AMENDED AND RESTATED CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of the 11th day of March 2009 by and between Gabriele M. Cerrone (“Consultant”) and Callisto Pharmaceuticals, Inc., a Delaware corporation (the “Company”).